This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Bioluminescent imaging in an Alzheimer's disease (AD) mouse model tracking β -amyloid ($A\beta$) deposits	Mouse studies suggest that bioluminescent imaging of $A\beta$ levels in transgenic AD mouse models could help identify new AD therapeutics. In transgenic AD mouse models that expressed a <i>luciferase</i> gene, bioluminescent signals correlated with $A\beta$ deposit levels in the brain, increasing over time as disease progressed. Next steps could include using the model to test AD therapeutics. SciBX 4(7); doi:10.1038/scibx.2011.202 Published online Feb. 17, 2011	Patent and licensing status unavailable	Watts, J.C. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Jan. 24, 2011; doi:10.1073/pnas.1019034108 Contact: Stanley B. Prusiner, University of California, San Francisco, Calif. e-mail: stanley@ind.ucsf.edu